Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.41 |
| ▸ | FABP7 | O15540 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | GPR3 | P46089 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2730698 | 0.81 | CA1 (0.57) | CA1CA2HTR2AKMT2AFABP5 | |
| SCHEMBL456018 | 0.77 | CA1 (0.53) | CA1CA2HTR2AKMT2AFABP5 | |
| SCHEMBL20362789 | 0.77 | CA1 (0.53) | CA1CA2HTR2AKMT2AFABP5 | |
| SCHEMBL15372784 | 0.77 | CA1 (0.53) | CA1CA2HTR2AKMT2AFABP5 | |
| SCHEMBL31501939 | 0.77 | CA1 (0.53) | CA1CA2HTR2AKMT2AFABP5 | |
| SCHEMBL4992955 | 0.77 | CA1 (0.53) | CA1CA2HTR2AKMT2AFABP5 | |
| SCHEMBL31370732 | 0.77 | HTR2A (0.58) | CA1CA2HTR2AKMT2AFABP5 | |
| SCHEMBL28050 | 0.77 | HTR2A (0.58) | CA1CA2HTR2AKMT2AFABP5 | |
| SCHEMBL158137 | 0.77 | CA1 (0.53) | CA1CA2HTR2AKMT2AFABP5 | |
| SCHEMBL17167370 | 0.75 | KMT2A (0.56) | CA1CA2HTR2AKMT2AFABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1417 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4678680-A1 | METHOD FOR PRODUCING POLYALKYLENE OXIDE-MODIFIED PHOSPHOLIPID | NOF Corporation (JP) | 2026-01-14 | — | — | EP | claimed |
| WO-2024185762-A1 | METHOD FOR PRODUCING POLYALKYLENE OXIDE-MODIFIED PHOSPHOLIPID | 日油株式会社 | 2024-09-12 | — | — | WO | claimed |
| US-12611461-B2 | Bioorthogonal compositions | TAMBO, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-12611462-B2 | Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof | CITY OF HOPE (US) | 2026-04-28 | — | — | US | disclosed |
| US-12589162-B2 | Trans-cyclooctene prodrug of monomethyl auristatin E | TAMBO, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-12570621-B2 | Short-acting 3,4-methylenedioxymethamphetamine (MDMA) analogs incorporating benzothiazole | APOAPSIS HOLDINGS, LLC (US) | 2026-03-10 | — | — | US | disclosed |
| US-12569466-B2 | Short-acting psychoactive compounds of the MDMA class | APOAPSIS HOLDINGS, LLC (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260028662-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | PROMEGA CORP (US) | 2026-01-29 | — | — | US | disclosed |
| US-12527874-B2 | Bioorthogonal compositions | TAMBO, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4678680-A1 | METHOD FOR PRODUCING POLYALKYLENE OXIDE-MODIFIED PHOSPHOLIPID | NOF Corporation (JP) | 2026-01-14 | — | — | EP | disclosed |
| US-20260007759-A1 | TRANS-CYCLOOCTENE PRODRUG OF MONOMETHYL AURISTATIN E | TAMBO, INC. | 2026-01-08 | — | — | US | disclosed |
| US-20020183325-A1 | Therapy of disease of the human or animal body mediated by poly ADP-ribosyltransferase (PARP) by administering phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2002-12-05 | — | — | US | disclosed |
| WO-2002090334-A1 | ISOQUINOLINONE DERIVATIVES AS PARP INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002036576-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2002-05-10 | — | — | WO | disclosed |
| WO-2002030879-A2 | CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS | PROLIFIX LIMITED (GB) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002030932-A2 | N8,N13-DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002026696-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | PROLIFIX LIMITED (GB) | 2002-04-04 | — | — | WO | disclosed |
| WO-2002026703-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN ETHER LINKAGE AS HDAC INHIBITORS | PROLIFIX LIMITED (GB) | 2002-04-04 | — | — | WO | disclosed |
| WO-2002008193-A2 | THERAPEUTIC ACRIDONE AND ACRIDINE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-01-31 | — | — | WO | disclosed |
| WO-2001093841-A2 | BARBITURIC ACID ANALOGS AS THERAPEUTIC AGENTS | NOVUSPHARMA S.P.A. (IT) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570621-B2 | Short-acting 3,4-methylenedioxymethamphetamine (MDMA) analogs incorporating benzothiazole | SLC6A3, SLC6A2, HTR2C | CA1 4822/4885CA2 4755/4885HTR2A 31/4885 |
| US-20020183325-A1 | Therapy of disease of the human or animal body mediated by poly ADP-ribosyltransferase (PARP) by administering phthalazinone derivatives | PARP1, PARP11, PARP3 | CA1 1684/4885CA2 2855/4885HTR2A 1651/4885 |
| US-12589162-B2 | Trans-cyclooctene prodrug of monomethyl auristatin E | AURKC, AURKA, QPCT | CA1 148/4885CA2 582/4885HTR2A 4536/4885 |
| US-12611462-B2 | Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof | STAT3, NSUN2, STAT1 | CA1 2612/4885CA2 3575/4885HTR2A 4050/4885 |
| US-20260028662-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | RNGTT, VIP, PREP | CA1 3819/4885CA2 3928/4885HTR2A 3557/4885 |
| US-12611461-B2 | Bioorthogonal compositions | ACVRL1, FCGR2A, CHIT1 | CA1 169/4885CA2 447/4885HTR2A 4159/4885 |
| US-20260007759-A1 | TRANS-CYCLOOCTENE PRODRUG OF MONOMETHYL AURISTATIN E | CCL5, CXCL10, SLC7A11 | CA1 203/4885CA2 887/4885HTR2A 4553/4885 |
| US-12569466-B2 | Short-acting psychoactive compounds of the MDMA class | HTR2C, SLC6A2, DRD2 | CA1 4795/4885CA2 4605/4885HTR2A 11/4885 |
| US-12527874-B2 | Bioorthogonal compositions | CD44, FLNA, H1-5 | CA1 1888/4885CA2 3888/4885HTR2A 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.